We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Zscaler
ZS
$28.9B
| $1.32M | ﹤0.01% |
8,956
-16,452
| -65% | -$2.91M |
|
|
ITCI
1302
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.32M | ﹤0.01% |
23,047
+13,222
| +135% | +$750K |
|
|
CIO
1303
DELISTED
City Office REIT
CIO
| $1.31M | ﹤0.01% |
101,283
+31,376
| +45% | +$444K |
|
|
CSR
1304
Centerspace
CSR
$920M
| $1.3M | ﹤0.01% |
15,939
+2,245
| +16% | +$197K |
|
1305
Edison International
EIX
$26.9B
| $1.29M | ﹤0.01% |
20,640
-14,657
| -42% | -$993K |
|
1306
Sonic Automotive
SAH
$2.55B
| $1.29M | ﹤0.01% |
35,292
+14,945
| +73% | +$642K |
|
1307
Zurn Elkay Water Solutions
ZWS
$8.6B
| $1.29M | ﹤0.01% |
47,376
-9,948
| -17% | -$302K |
|
|
SJI
1308
DELISTED
South Jersey Industries, Inc.
SJI
| $1.29M | ﹤0.01% |
37,716
-4,844
| -11% | -$166K |
|
1309
Four Corners Property Trust
FCPT
$2.69B
| $1.29M | ﹤0.01% |
48,384
-14,466
| -23% | -$394K |
|
1310
Tredegar Corp
TG
$275M
| $1.29M | ﹤0.01% |
128,689
-13,596
| -10% | -$158K |
|
1311
Walker & Dunlop
WD
$1.48B
| $1.28M | ﹤0.01% |
13,303
-1,898
| -12% | -$209K |
|
1312
Preferred Bank
PFBC
$1.26B
| $1.27M | ﹤0.01% |
18,700
+368
| +2% | +$25.2K |
|
1313
Arlo Technologies
ARLO
$1.59B
| $1.27M | ﹤0.01% |
202,563
-2,800
| -1% | -$20.5K |
|
1314
Pricesmart
PSMT
$5.33B
| $1.27M | ﹤0.01% |
17,720
-7,267
| -29% | -$563K |
|
1315
Houlihan Lokey
HLI
$8.77B
| $1.27M | ﹤0.01% |
16,053
-124
| -0.8% | -$10.4K |
|
1316
SPS Commerce
SPSC
$2.7B
| $1.26M | ﹤0.01% |
11,186
-12,673
| -53% | -$1.43M |
|
1317
WesBanco
WSBC
$4.05B
| $1.26M | ﹤0.01% |
39,635
-4,860
| -11% | -$160K |
|
1318
Cohu
COHU
$2.5B
| $1.25M | ﹤0.01% |
45,243
+2,514
| +6% | +$69.4K |
|
1319
United Parks & Resorts
PRKS
$2B
| $1.25M | ﹤0.01% |
28,397
-4,372
| -13% | -$254K |
|
1320
Abercrombie & Fitch
ANF
$5.24B
| $1.25M | ﹤0.01% |
74,092
+20,933
| +39% | +$578K |
|
1321
Pediatrix Medical
MD
$2.12B
| $1.25M | ﹤0.01% |
60,130
+35,966
| +149% | +$734K |
|
|
PRMW
1322
DELISTED
Primo Water Corporation
PRMW
| $1.25M | ﹤0.01% |
93,070
-21,740
| -19% | -$306K |
|
1323
Weis Markets
WMK
$1.76B
| $1.24M | ﹤0.01% |
16,668
-2,822
| -14% | -$219K |
|
1324
Chesapeake Utilities
CPK
$3.22B
| $1.24M | ﹤0.01% |
9,573
+1,568
| +20% | +$205K |
|
1325
Resources Connection
RGP
$144M
| $1.24M | ﹤0.01% |
60,749
-7,395
| -11% | -$132K |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.